Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Targeting insulin-like growth factor type 1 receptor in cancer therapy Atzori F; Traina TA; Ionta MT; Massidda BTarget Oncol 2009[Dec]; 4 (4): 255-66It is believed that the insulin-like growth factor receptor type 1 (IGF-1R) signaling pathway plays a pivotal role in cancer growth, progression, and resistance to anticancer therapies. Strategies are being developed to block IGF-1R as an anticancer treatment. We reviewed several potential strategies for disrupting the IGF axis. We also reviewed the effects of two drugs that target the IGF-1R: monoclonal antibodies and tyrosine kinase inhibitors. Preliminary results of studies involving these agents provided a foundation for ongoing clinical trials, whose results in the near future will help us understand how to incorporate anti IGF-1R strategies into the current anticancer armamentarium.|*Drug Delivery Systems[MESH]|Antineoplastic Agents/*administration & dosage/therapeutic use[MESH]|Drug Synergism[MESH]|Humans[MESH]|Male[MESH]|Neoplasms/drug therapy/*metabolism[MESH]|Protein Kinase Inhibitors/*administration & dosage/therapeutic use[MESH]|Receptor, IGF Type 1/*antagonists & inhibitors[MESH]|Signal Transduction/drug effects[MESH] |